Earnings summaries and quarterly performance for PROCEPT BioRobotics.
Executive leadership at PROCEPT BioRobotics.
Board of directors at PROCEPT BioRobotics.
Research analysts who have asked questions during PROCEPT BioRobotics earnings calls.
BV
Brandon Vazquez
William Blair & Company, L.L.C.
6 questions for PRCT
Also covers: ALGN, CBLL, CVRX +17 more
JJ
Joshua Jennings
TD Cowen
6 questions for PRCT
Also covers: ABT, ALUR, ATEC +21 more
RN
Richard Newitter
Truist Securities
6 questions for PRCT
Also covers: AXNX, BBNX, DXCM +19 more
NT
Nathan Treybeck
Wells Fargo Securities
5 questions for PRCT
Also covers: IRTC, ITGR, LMAT +2 more
MO
Matthew O'Brien
Piper Sandler & Co.
4 questions for PRCT
Also covers: APYX, ATEC, ATRC +18 more
MS
Michael Sarcone
Jefferies
4 questions for PRCT
Also covers: ALC, ALGN, AXGN +12 more
Mike Kratky
Leerink Partners
4 questions for PRCT
Also covers: AXGN, DXCM, INSP +5 more
Chris Pasquale
Nephron Research LLC
3 questions for PRCT
Also covers: ALC, AXGN, BSX +9 more
Christopher Pasquale
Nephron Research
3 questions for PRCT
Also covers: ALC, AXGN, BSX +12 more
CB
Craig Bijou
Bank of America Securities
3 questions for PRCT
Also covers: BLCO, COO, FNA +9 more
Patrick Wood
Morgan Stanley
3 questions for PRCT
Also covers: ALC, BDX, BLCO +20 more
Ryan Zimmerman
BTIG
3 questions for PRCT
Also covers: ALC, CARL, GEHC +24 more
SK
Suraj Kalia
Oppenheimer & Co. Inc.
3 questions for PRCT
Also covers: ABT, AORT, ATRC +14 more
Ben...
Stephens Inc.
2 questions for PRCT
Also covers: ABBNY, CPRX, HBAN +1 more
DA
Danielle Antalffy
UBS
2 questions for PRCT
Also covers: ATRC, BAX, BBNX +12 more
MO
Matthew O'Brien
Piper Sandler
2 questions for PRCT
Also covers: BBNX, CNMD, DXCM +5 more
Michael Kratky
Leerink Partners
2 questions for PRCT
Also covers: AXGN, BBNX, DXCM +6 more
Stephanie Piazzola
Bank of America
2 questions for PRCT
Also covers: BBNX, CBLL, IRTC +3 more
MC
Mason Carrico
Stephens Inc.
1 question for PRCT
Also covers: AKYA, CDNA, CSTL +13 more
Recent press releases and 8-K filings for PRCT.
PROCEPT BioRobotics Provides 2026 and 2027 Financial Guidance and Strategic Updates
PRCT
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- PROCEPT BioRobotics provided 2026 revenue guidance of $390 million-$410 million, representing 27%-33% growth, and expects 2027 revenue to exceed $500 million, with growth in the 25%-30% range.
- The company anticipates gross margins of 65% in 2026, potentially reaching 70% in 2027, primarily due to the shift towards a procedure-based business.
- PROCEPT BioRobotics projects an EBITDA loss of $30 million-$17 million in 2026, with an expectation to become EBITDA positive in Q4 2026 and achieve positive EBITDA of $25 million-$30 million in 2027.
- Strategic changes include the elimination of end-of-quarter volume discounts, which is expected to boost the handpiece Average Selling Price (ASP) to about $3,500 in 2026, and a restructuring of the sales organization to improve efficiency and alignment.
- The company aims to be cash flow positive by the end of 2027 and plans to leverage its balance sheet to offer operating lease placements starting in 2026 to expand market access.
2 days ago
PROCEPT BioRobotics Outlines 2026-2027 Financial Guidance and Strategic Initiatives
PRCT
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- PROCEPT BioRobotics projects 2026 revenue guidance of $390-$410 million (27%-33% growth) and expects 2027 revenue to exceed $500 million with 25%-30% growth. The company anticipates becoming EBITDA positive in Q4 2026 and reaching positive EBITDA of $25 million-$30 million in 2027.
- The company has eliminated end-of-quarter volume discounts, leading to an expected handpiece ASP of $3,500 in 2026, a $300 increase from historical levels, and projects gross margins to reach 65% in 2026 and up to 70% in 2027.
- PROCEPT BioRobotics aims to be the leading procedure for BPH in 2026, targeting share from TURP, where it is currently only 10% penetrated. The company is also pursuing Aquablation for prostate cancer, with the WATERFORCE study expected to complete procedures by mid-2026.
- To drive growth, the company will focus on same-facility procedure growth, introduce operating leases in 2026, and invest in patient education to increase awareness, which is currently at 1%-2% unaided awareness.
2 days ago
PROCEPT BioRobotics Updates 2026-2027 Financial Guidance and Strategic Initiatives
PRCT
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- PROCEPT BioRobotics provided 2026 revenue guidance of $390 million-$410 million, representing 27%-33% growth, and anticipates 2027 revenue growth of 25%-30%, expecting to exceed $500 million. The company also guided for 60,000-64,000 procedures in 2026.
- The company expects to be EBITDA positive in Q4 2026 and projects positive EBITDA of $25 million-$30 million in 2027, which is a $60 million improvement over 2025 at the high end. Gross margins are guided to 65% in 2026 and could reach 70% in 2027.
- Strategic operational changes include the elimination of end-of-quarter volume discounts, which is expected to increase the Average Selling Price (ASP) to $3,500 in 2026 (a $300 increase). Other changes involve sales force realignment and a new launch strategy that reduced the time from purchase order to completing the first 10 cases by 50% in a pilot program.
- Key growth drivers include the recent Category I reimbursement effective January 1st , the increasing adoption of the HYDROS system, and future opportunities in international expansion and prostate cancer. The company is also exploring leasing pilot programs in 2026 to drive procedure growth.
- PROCEPT expects its cash balance to never fall below $175 million and projects becoming cash flow positive in Q4 2027.
2 days ago
PROCEPT BioRobotics Provides 2026-2027 Financial Guidance and Updates on Prostate Cancer Expansion
PRCT
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- PROCEPT BioRobotics issued 2026 revenue guidance of $390 million to $410 million, representing 27% to 33% growth, and projects 25% to 30% annual revenue growth in 2027.
- The company anticipates a 65% gross margin in 2026, targeting 68% to 70% in 2027, and expects an adjusted EBITDA loss of $30 million to $17 million in 2026, moving to a gain of $25 million to $30 million in 2027, with positive EBITDA assumed in Q4 2026.
- Aquablation procedures are projected to reach 60,000 to 64,000 in 2026.
- PROCEPT BioRobotics is expanding into prostate cancer treatment with the WATER IV PCa Study, a randomized trial comparing Aquablation to radical prostatectomy, which is on pace to complete all procedures by mid-2026.
2 days ago
PROCEPT BioRobotics Corporation Provides Financial Guidance and Strategic Update
PRCT
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- PROCEPT BioRobotics Corporation reported total revenue of $309 million in 2025, demonstrating a 60% compound annual growth rate (CAGR) from 2022, and achieved a gross margin of 63.7% in the same year.
- The company issued 2026 revenue guidance of $390 million to $410 million, representing 27% to 33% growth, and anticipates an adjusted EBITDA loss between $30 million and $17 million.
- For 2027, PROCEPT BioRobotics projects an adjusted EBITDA gain of $25 million to $30 million and targets a gross margin range of 68% to 70%.
- Strategic initiatives include accelerating Aquablation procedure growth and expanding applications into prostate cancer treatment, with the WATER IV clinical trial on pace to complete all procedures by mid-2026.
2 days ago
PROCEPT BioRobotics Details Multi-year Financial Outlook and Strategic Plan
PRCT
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- PROCEPT BioRobotics provided financial guidance for 2026 and 2027, projecting annual revenue growth of 27% - 33% and 25% - 30%, respectively, with gross margins expected to reach 65% in 2026 and 68% - 70% in 2027.
- The company anticipates achieving positive adjusted EBITDA in Q4 2026 and an adjusted EBITDA gain of $25 to $30 million in 2027.
- The strategic plan focuses on driving leadership in BPH through Aquablation procedure growth and expanding into longer-term opportunities like international markets and prostate cancer treatment, with WATER IV trial procedures expected to complete by mid-2026.
2 days ago
PROCEPT BioRobotics Announces Q4 2025 Results and Updates 2026 Guidance
PRCT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- PROCEPT BioRobotics reported Q4 2025 total revenue of $76.4 million, a 12% year-over-year increase, with 12,200 U.S. procedures completed, representing 69% annual growth. The company recorded a net loss of $29.8 million and an Adjusted EBITDA loss of $19 million for the quarter.
- The company issued 2026 full-year revenue guidance of $390 million-$410 million, reflecting 27%-33% growth over 2025, and expects U.S. procedures to be between 60,000 and 64,000, growing 39%-48%. They anticipate a full-year 2026 Adjusted EBITDA loss of $30 million-$17 million, with positive EBITDA expected in Q4 2026.
- Management implemented strategic changes, including eliminating bulk purchase discounts for handpieces and realigning the sales team, which led to handpiece unit sales being approximately 80% of procedures in Q4 2025 and an average selling price of $3,340, up 5% sequentially. For 2026, they now model a 1-to-1 ratio of handpiece sales to procedures, a significant change from historical trends, and expect a U.S. handpiece average selling price of $3,500.
- For Q1 2026, the company projects total revenues of $79 million-$82 million and U.S. procedures between 12,000-12,800.
3 days ago
PROCEPT BioRobotics Reports Q4 2025 Results and Updates 2026 Guidance
PRCT
Earnings
Guidance Update
Demand Weakening
- PROCEPT BioRobotics reported Q4 2025 total revenue of $76.4 million, representing 12% year-over-year growth, with a net loss of $29.8 million and a gross margin of 60.6%.
- The company reset its full-year 2026 total revenue guidance to $390 million-$410 million, reflecting 27%-33% annual growth, and expects 60,000-64,000 U.S. procedures.
- This updated guidance is primarily driven by changes in business practices, including the elimination of bulk purchase discounts, which is expected to align handpiece unit sales more closely with procedure volumes and result in an average selling price of approximately $3,500 for handpieces in 2026.
- Q4 2025 gross margin was negatively impacted by a one-time voluntary field action that contributed approximately 240 basis points of pressure.
3 days ago
PROCEPT BioRobotics Reports Q4 and Full Year 2025 Financial Results and Updates 2026 Guidance
PRCT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- PROCEPT BioRobotics reported total revenue of $76.4 million for the fourth quarter of 2025, an increase of 12% compared to the prior year, and a net loss of $29.8 million.
- For the full year 2025, revenue was $308.1 million, representing a 37% increase compared to 2024, with a net loss of $95.6 million.
- The company provided full year 2026 revenue guidance in the range of $390 million to $410 million, which represents projected growth of 27% to 33% compared to the prior year.
- U.S. procedures for Q4 2025 were approximately 12,200, an increase of 69% compared to the prior year period, and the U.S. install base grew to 718 systems as of December 31, 2025.
3 days ago
PROCEPT BioRobotics Reports Q4 2025 Financial Results and Updates 2026 Guidance
PRCT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- PROCEPT BioRobotics reported total revenue of $76.4 million for Q4 2025, an increase of 12% compared to the prior year, and full-year 2025 revenue of $308.1 million, up 37% from 2024.
- For Q4 2025, the company recorded a net loss of $29.8 million and an Adjusted EBITDA loss of $19.0 million.
- The company provided full-year 2026 revenue guidance in the range of $390 million to $410 million, representing 27% to 33% growth, and an Adjusted EBITDA loss guidance between $30 million and $17 million.
- Operational highlights for Q4 2025 include approximately 12,200 U.S. procedures, an increase of about 69% year-over-year, and an ending U.S. install base of 718 systems, a 42% increase.
3 days ago
Quarterly earnings call transcripts for PROCEPT BioRobotics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more